Poland· PL-100129386
Avastin
A bevacizumab product containing bevacizumabum, registered in Poland by Roche Registration GmbH. The same ATC class is registered in 13 of our 19 countries.
Checked against URPL (Poland) on
Informational only — not a medical device.
Where it is registered
Bevacizumab is registered in 13 of 19 countries.
Countries holding a registration under ATC L01FG01 (bevacizumab), each read from that country’s own register.
- This record: Poland, from URPL (Poland)
- 8 of them publish a price we can compare per daily dose
Bevacizumab · ATC L01FG01
13 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of bevacizumab costs, country by country.
Normalised to the WHO defined daily dose (45 mg), so markets compare like for like.
- 1 market with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Bevacizumab · price per daily dose (45 mg)
USD · FX 28 Sept 2026
- CH Switzerland$141.13
The record
At a glance
URPL (Poland)- Active substance
- Bevacizumabum
- Manufacturer
- Roche Registration GmbH
- Country
- Poland (PL)
- ATC code
- L01FG01
- ATC class
- Bevacizumab
- Defined daily dose
- 45 mg, P
- Reimbursed
- Not published by this register
- Source register
- URPL (Poland)
- Last checked
- September 27, 2026
Packs & prices · 2
- gtin05909990010486
- gtin05909990010493
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
22 interactions on record for bevacizumab.
Graded by severity as the source publishes them — 6 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Bevacizumab · interactions on record
22 records
- 6 severe
- 16 moderate
Most severe, free to view
- SunitinibL01EX01severe
- PanitumumabL01FE02severe
- PanitumumabL01XC08severe
- SunitinibL01XE04severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Bevacizumab in 15 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaABEVMYBiosimilar Collaborations Ireland Limited, Dublin
- BelgiumAbevmy 25 mg/mlBiosimilar Collaborations Ireland
- FinlandAbevmyBiosimilar Collaborations Ireland Limited
- IrelandAbevmy 25 mg/mL concentrate for solution for infusionBiosimilar Collaborations Ireland Limited
- IcelandAbevmyBiosimilar Collaborations Ireland Limited
- SwedenAbevmy 25 mg/ml Koncentrat till infusionsvätska, lösningBiosimilar Collaborations Ireland Limited
- NorwayAlymsysMabxience Research SL
- United KingdomAbevmy 100mg/4ml concentrate for solution for infusion vialsBiocon Biologics Ireland Ltd
Authorised across Europe · EMA
The same active substance is authorised in 4 EEA countries. Names it is sold under:
- United Kingdom (Northern Ireland) · Oyavas
- Iceland · Abevmy, Alymsys
- Liechtenstein · Abevmy, Alymsys
- Norway · Abevmy, Alymsys
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/83bdc37c-4d93-4ec0-bf2d-475ec809ef7e GET /v1/drugs/83bdc37c-4d93-4ec0-bf2d-475ec809ef7e?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Koncentrat do sporządzania roztworu do infuzji",
"source": "urpl",
"strength": "25 mg/ml",
"packaging": "05909990010486 ¦ Rpz ¦ EU/1/04/300/001 ¦ 12676\n1 fiol. 4 ml\n05909990010493 ¦ Rpz ¦ EU/1/04/300/002 ¦ 12731\n1 fiol. 16 ml",
"substance": "Bevacizumabum 25 mg/ml",
"common_name": "Bevacizumabum",
"pl_product_id": "100129386",
"pozwolenie_nr": null,
"auth_procedure": "CEN",
"authorisation_validity": null
}See everything about bevacizumab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.